OTC · CIK 0001053369
ELTP ELITE PHARMACEUTICALS INC /NV/
Insider trading from SEC Form 4. Last filing 33 d ago. Close $0.26 on Oct 9, 2026, +18% from the 52-week low and -62% from the high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ELITE PHARMACEUTICALS INC /NV/, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 10Weak | Barry H Dash director buy | $8,610 30,000 shares | +1% | - | |
| 38Weak | Douglas Plassche EVP Operations sell | $499k 800,000 shares | -19% | +100% from low-17% from high | |
| 18Weak | Elite Pharmaceuticals Inc /nv/ EVP Operations sell | $262k 500,000 shares | -22% | +72% from low-29% from high | |
| 31Weak | Kirko Kirkov Chief Commercial Officer buy | $9,640 16,366 shares | - | +63% from low-32% from high | |
| 25Weak | Douglas Plassche EVP Operations sell | $116k 200,000 shares | -8% | +84% from low-23% from high | |
| 54Moderate | Douglas Plassche SVP of Operations sell | $562k 1,133,932 shares | -100% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 23, 2024 | Plassche Douglas Officer | 1,133,932 0.11% of outstanding | $680k | Oct 23, 2024 | none |
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Barry H Dash director | POpen-market purchase Common Stock | +30,000 | $0.29 | $8,610 | 3,265,555 | 33 d ago |
| Jan 9, 2026 | Douglas Plassche EVP Operations | MOption exercise Stock Options (right to buy) | +2,500,000 | $0.03 | $75k | 6,000,000 | Jan 13, 2026 |
| Jan 9, 2026 | Douglas Plassche EVP Operations | MOption exercise Stock Options (right to buy)derivative | -2,500,000 | $0.00 | $0 | 0 | Jan 13, 2026 |
| Oct 2, 2025 | Douglas Plassche EVP Operations | SOpen-market sale common stock | -800,000 | $0.62 | $499k | 3,500,000 | Oct 3, 2025 |
| Aug 22, 2025 | Elite Pharmaceuticals Inc /nv/ EVP Operations | SOpen-market sale Common Stock | -500,000 | $0.52 | $262k | 1,800,000 | Aug 26, 2025 |
| Aug 25, 2025 | Elite Pharmaceuticals Inc /nv/ EVP Operations | MOption exercise Common Stock | +2,500,000 | $0.03 | $75k | 4,300,000 | Aug 26, 2025 |
| Aug 25, 2025 | Elite Pharmaceuticals Inc /nv/ EVP Operations | MOption exercise Stock Options (right to buy)derivative | -2,500,000 | $0.00 | $0 | 2,500,000 | Aug 26, 2025 |
| Jul 10, 2025 | Kirko Kirkov Chief Commercial Officer | POpen-market purchase Common Stock | +16,366 | $0.59 | $9,640 | 16,366 | Jul 25, 2025 |
| Jul 8, 2025 | Douglas Plassche EVP Operations | SOpen-market sale Stock Options (right to buy) | -200,000 | $0.58 | $116k | 2,300,000 | Jul 10, 2025 |
| Jul 3, 2025 | Douglas Plassche EVP Operations | MOption exercise Stock Options (right to buy) | +2,500,000 | $0.03 | $75k | 2,500,000 | Jul 8, 2025 |
| Jul 3, 2025 | Douglas Plassche EVP Operations | MOption exercise Stock Options (right to buy)derivative | -2,500,000 | $0.00 | $0 | 5,000,000 | Jul 8, 2025 |
| Oct 23, 2024 | Douglas Plassche SVP of Operations | SOpen-market sale Common Stock | -800,000 | $0.49 | $392k | 333,932 | Oct 28, 2024 |
| Oct 24, 2024 | Douglas Plassche SVP of Operations | SOpen-market sale Common Stock | -333,932 | $0.51 | $170k | 0 | Oct 28, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Barry H Dashdirector
- Elite Pharmaceuticals Inc /nv/EVP Operations
- Kirko KirkovChief Commercial Officer
- Douglas PlasscheEVP Operations
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.